Securities Times reporter Ruan Yunsheng

  In the face of fluctuations in the broader market and individual stocks, more and more A-share listed companies have joined the repurchase army.

According to statistics from Oriental Fortune, since 2022, about 200 listed companies have launched repurchase plans.

In February, 109 listed companies have released repurchase plans or announced progress, mostly in electronics, medical and medical equipment, and chemical industries.

Among them, Hengli Petrochemical has invested about 500 million yuan to implement, and Maiwei’s share repurchase limit is as high as 650 yuan per share.

  In November 2021, Hengli Petrochemical plans to use its own funds or self-raised funds in the next 12 months to repurchase the company's shares through centralized bidding. The total repurchase funds will be between 500 million and 1 billion yuan; the repurchase price is Not more than 35 yuan / share.

As of February 14, the company has implemented its first repurchase, involving 19,289,600 shares, accounting for 0.27% of the company's total share capital. The transaction price ranges from 24.8 yuan/share to 26.51 yuan/share, and the total amount paid is about 500 million. Yuan.

  In the first three quarters of last year, Hengli Petrochemical achieved a net profit of about 12.7 billion yuan, a year-on-year increase of 28.46%. Among them, the company's profit growth rate declined in the third quarter, and its net profit fell by about 10% month-on-month.

At the same time, the company continues to expand production.

In January this year, Hengli Petrochemical disclosed an investment of 1.6 million tons/year of high-performance resin and new material projects. The total investment is expected to be about 20 billion yuan to accelerate the layout of electronic-grade new materials. In addition, the company will invest 4 billion yuan for an annual output of 2.6 million yuan. tons of high-performance polyester works.

From the perspective of market performance, the share price of Hengli Petrochemical hit a high of 49.03 yuan per share in February last year, and then the share price continued to fall, with a cumulative decline of more than 50%; since the company launched the repurchase plan, the share price rebounded and rose 17.63%, the latest closing at 25.16 Yuan/share.

  As the leading target of fingerprint identification chips, the stock price of Huiding has continued to fall since hitting a high of 386.75 yuan per share on February 26, 2020. The latest closing market value has shrunk to 41.5 billion yuan, and the closing price is 90.75 yuan per share.

Since the first quarter of 2020, the company's profit growth rate has continued to decline; in the third quarter of last year, the company's net profit dropped by about 60%.

On February 12, Goodix Technology disclosed its repurchase plan, planning to repurchase the shares issued by the company with its own funds of 400 million to 500 million yuan, all of which will be used to implement the company's employee stock ownership plan.

The repurchase price is not more than 126 yuan per share (inclusive), and the repurchase period is not more than 12 months from the date when the board of directors considers and approves the share repurchase plan, that is, from February 11, 2022 to February 2023 10th.

On the evening of February 14, Huiding Technology once again announced the repurchase report. According to the upper limit, the expected number of shares to be repurchased is about 3.9683 million shares, accounting for about 0.87% of the company's total share capital; according to the lower limit, the expected number of shares to be repurchased 0.69% of the company's total share capital.

  Hang Seng Electronics also disclosed on the evening of February 14 that it plans to repurchase shares at a price of 100 million to 150 million yuan, and the repurchase price does not exceed 80 yuan per share. The repurchased shares will be used for equity incentives or employee stock ownership plans.

On the same day, Maiwei disclosed its plan to repurchase shares at a price of 163 million to 325 million yuan, with the repurchase price cap not exceeding 650 yuan per share, ranking first among listed companies that have disclosed repurchase plans.

The shares repurchased by the company will also be used for equity incentives or employee stock ownership plans. Calculated according to the upper and lower limits of the repurchased shares, they account for about 0.23% to 0.46% of the company's issued share capital.

The performance forecast shows that Maiwei shares is expected to achieve a profit of 580 million to 680 million yuan last year, an increase of 47.05% to 72.4% over the same period of the previous year;

The sales volume of the company's main product, solar cell screen printing equipment, has steadily increased, making the company's net profit maintain a high growth rate.

However, in terms of market performance, Maiwei's share price has fallen by nearly 40% since mid-December last year.

  Aide Bio also launched a repurchase plan. It plans to spend 100 million to 200 million yuan to repurchase shares. The repurchase price does not exceed 95 yuan per share. The repurchased shares will be used to implement equity incentives or employee stock ownership plans.

Calculated based on the upper and lower limits of the total repurchase funds, the shares repurchased account for about 0.47% to 0.95%.

In the first three quarters of last year, Aide Bio's operating costs increased by 70% year-on-year, far exceeding the growth rate of revenue. Net profit achieved 177 million yuan, an increase of about 40% year-on-year. Among them, the net profit in the third quarter decreased by nearly 4% month-on-month.

The company pointed out that the revenue growth is mainly due to the increase in the sales of multi-gene combination reagent products, and the cost of multi-gene combination reagents is relatively high; the cost of testing services has increased, and the cost of cold chain transportation of products has increased.

Since the release of the third quarterly report, the company's stock price has continued to fall since late December last year, with a cumulative decline of more than 36%.